Type of information: Initiation of patient enrollment
Announcement: initiation of patient enrollment
Company: Gemini Therapeutics (USA)
Disease: geographic atrophy (GA) secondary to dry AMD.
Therapeutic area: Ophthalmological diseases
Latest news: • On January 9, 2020, Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry age-related macular degeneration (AMD) and linked ocular disorders, announced it has initiated enrollment in its Phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. CFH risk variants are reported to occur in greater than 40% of patients with dry AMD and are strongly associated with the risk of developing the disease. The complement system, of which CFH is a modulator, is dysregulated in patients with these risk variants and results in amplification of aberrant inflammatory responses in the eye. Over time this dysregulation leads to damage to the macular region of the retina.